Business context and reporting period
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) filed this Form 8-K to report results of its September 24, 2026 annual meeting. The report was signed September 29, 2026. This filing reports corporate and stockholder matters, not quarterly or annual financial results.
Key financial and capital matters
- The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures.
- Stockholders approved an increase of 323,542 shares in the 2022 Successor Equity Incentive Plan reserve, bringing shares available for awards to 1,000,000.
- Stockholders approved issuance of up to 960,000 common shares upon exercise of Series C-1 warrants issued in a private placement that closed July 1, 2026. Approval does not establish that the warrants have been exercised.
- As of the July 27, 2026 record date, 3,567,592 common shares were outstanding and entitled to vote. A quorum of 2,155,341 shares was represented at the meeting.
Meeting results and changes
- Quang X. Pham was elected as a Class I director to serve until the 2029 annual meeting and qualification of a successor.
- Stockholders ratified WithumSmith+Brown, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The plan amendment passed with 694,746 votes for and 352,409 against. The warrant proposal passed with 1,011,206 votes for and 34,449 against.
- An adjournment proposal also passed, but the meeting was not adjourned because the plan and warrant proposals received the required approval.
Outlook, risks, and unusual items
The filing gives no financial guidance or operating outlook. The expanded equity-award pool and authorization for up to 960,000 warrant shares may dilute existing stockholders if awards are granted or warrants are exercised. The filing does not state the expected timing or likelihood of such issuance.
Important facts for investors to verify
- Review the full text of Amendment No. 2 to the 2022 Plan, filed as Exhibit 10.1, for award terms and plan provisions.
- Review the July 1, 2026 private-placement disclosures and warrant terms to assess exercise conditions and potential dilution.
- Consult the company’s financial filings for current cash, liquidity, operating results, and any updated business outlook; those items are not provided in this 8-K.